Effect of alfacalcidol on osteoporosis induced by large dose glucocorticoid treatment in glomerulonephritis patients

Abstract

Abstract: AIM:To observe the effect of alfacalcidol on osteoporosis induced by large dose glucocorticoid treatment in glomerulonephritis patients. METHODS: 28 patients with glomerulonephritis receiving glucocorticoids were divided into two groups randomly. 16 patients received calcium carbonate 750 mg three times plus alfacalcidol 1 μg one time orally a day (treatment group), and 12 patients received calcium carbonate 750 mg three times orally a day (control group). Bone mineral density (BMD) in the lumbar spine (L2-4) and the femoral neck were measured by dual-energy X-ray absorptiometry (DEXA). Intact parathyroid hormone (iPTH), serum albumin (ALB), serum calcium and phosphorus were detected before and 3, 6 months after treatment. RESULTS: BMD in the treatment group at the sixth month were higher than control group (lumbar spine 0.967±0.105, 0.896±0.131, P<0.05; femoral neck 1.078±0.124, 0.925±0.107, P<0.05). BMD in the control group at the sixth month were lower than those before treatment. There were no statistical differences in iPTH, ALB, serum calcium and phosphorus in two groups before and 3, 6 months after therapy. CONCLUSION: Alfacalcidol can decrease loss of bone mass in the lumbar spine and the femoral neck in the glomerulonephritis patients receiving glucocorticoid therapy.

Key words: Alfacalcidol, Glucocorticoid, Glomerulonephritis, Bone mineral density

CLC Number:

R692

YU Chang-qing, WANG Ke-ping, HANG Hong-dong, XIE Hua, LI Long-kai, WANG Jing. Effect of alfacalcidol on osteoporosis induced by large dose glucocorticoid treatment in glomerulonephritis patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 446-448.

References

[1] Van Staa TP, Lenfkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fracture[J]. J Bone Miner Res, 2000, 15(6): 993-1000.
[2] Fujita T, Satomura A, Hidaka M, et al. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephritic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy[J]. Calcif Tissue Int, 2000, 66(3): 195-199.
[3] Yonemura K, Kimura M, Miyaji T, et al. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patient with chronic glomerulonephritis[J]. Calcif Tissue Int, 2000, 66(2): 123-128.
[4] Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis[J]. Osteoporosi Int,1999, 9(1): 75-81.
[5] Peel NFA, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis[J]. Ann Rheum Dis, 1995, 54(10): 801-806.
[6] van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy[J]. Arthritis Rheum, 2003, 48(11): 3224-3229.
[7] Hong D, Chen HX, Ge RS, et al. The biological roles of extracellular and intracytoplasmic glucocorticoids in skeletal cells[J]. J Steroid Biochem Mol Biol, 2008, 111(3): 164-170.
[8] Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy[J]. Osteoporos Int, 2007, 8(10): 1319-28.
[9] Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast[J]. J Clin Invest, 2006, 116(8): 2152-2160.
[10] Azuma K, Urano T, Ouchi Y, et al. Glucocorticoid-induced gene tripartite motif-containing 63 (TRIM63) promotes differentiation of osteoblastic cells[J]. Endocr J,2010, 20(2):1-8.
[11] Amin S, LaValley MP, Simms RW, et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach[J]. Arthritis Rheum, 1999, 42(8): 1740-1751.
[12] 陈航,王梅. 原发性肾小球疾病糖皮质激素性骨质疏松预防治疗的临床研究[J]. 中华医学杂志,2005,85(31):2207-2210.
[13] 丁晓凯,刘毅,徐玉兰,等. 钙维生素D复合物单独与联用阿仑膦酸钠在治疗糖皮质激素引起骨量丢失疗效的观察[J]. 中国临床药理学与治疗学,2009,14(3):332-336.

[1]	ZHAO Yangting, CHEN Chongyang, PAN Binjing, LV Xiaoyu, LIU Jingfang. Trimethylamine N-oxide: the potential target for osteoporosis treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1161-1167.
[2]	GAO Jiarong, SHI Miaomiao, CHEN Hao, JIANG Hui, QIN Xiujuan. Effect of Qiteng Xiaozhuo granule mediating miR-339-5p on inflammatory indexes in rats with chronic glomerulonephritis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 457-465.
[3]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[4]	YU Chenchen, LIU Shuqun, LIU Jianlong, CAO Hong, LIU Xuejiao, CAI Xixi. Effects of curcumin on injury in hippocampal neurons and expression of blood corticosterone and SGK1 in hippocampal during global cerebral ischemia-reperfusion injury in hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 737-743.
[5]	ZHANG Danyang, DONG Xiaomin, ZHOU Xiaohuan, ZHANG Yue, ZHANG Juan, ZHOU Hebin. Gene microarray Analysis of Glucocorticoid resistance-related genes in Acute Lymphoblastic Leukemia based on GEO [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 272-277.
[6]	XUE Hua, LU Lili, XIANG Hui, QIAN Zhenhua. Curative efficacy of ulinastatin combined with hydrocortisone in treatment of severe sepsis secondary shock and effects on serum factor levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 313-317.
[7]	HE Xiaobin, LIN Xiaohua, LIU Shunli, OU Huanjiao. Evaluation on drug use of systemic glucocorticoid affected by the level of eosinophils in peripheral blood of the patients with acute exacerbation of chronic obstructive pulmonary disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 89-93.
[8]	LU Xiaohong，WANG Peiguang. Progress in the treatment of dermatomyositis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 836-840.
[9]	SHI Dejun, LIU Yi. Effects of different doses of metformin on bone metabolism and bone mineral density in elderly male patients with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1045-1049.
[10]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[11]	ZHANG Jun, XIE Yanyun, LI Zhi, TAO Lijian. Effects of splicing factor SRp40 on the expression of GRα/β mRNA and on glucocorticoid therapy for nephrotic syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 589-593.
[12]	SHANG Hongkai, FU Aiping, CHEN Lufang, TONG Jinyi, SI Qi. Effect and mechanism of dexamethasone on the function of placental transport of glucose [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1221-1226.
[13]	RAUN Yuan, WU Tian-feng, YUAN Fang, WEN Xiao-lin. Relationship between uric acid and bone mineral density in elderly type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 567-570.
[14]	LI Dong, XIA Chen-mei, CHEN Xia, YAN Hai-fan, FENG Chong-zhi. Effects of calcitriol on bone mineral density and bone metabolic markers in male patients with alcoholic cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 691-694.
[15]	LI Zhi, ZHANG Meng-ying, LU Jin-ming, XU Liang, CHEN Lan-fang, MAO Tong-jun, XUAN Dan. Effects of glucocorticoid and cyclophosphamide on the human umbilical vein endothelial cell proliferation and ICAM-1 and MCP-1 expression level [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 366-370.